Hereditary Angioedema Therapeutics Market by Drug Class (Bradykinin B2 Receptor Antagonist, C1-Esterase Inhibitor, Kallikrein Inhibitor), Treatment Type, Route Of Administration

Description

List of Tables

The Hereditary Angioedema Therapeutics Market was valued at USD 36.59 billion in 2023, expected to reach USD 38.29 billion in 2024, and is projected to grow at a CAGR of 6.04%, to USD 55.19 billion by 2030.

Hereditary Angioedema (HAE) therapeutics focus on managing and treating this rare genetic disorder characterized by recurring episodes of severe swelling in different body parts. Necessity for these treatments arises due to the potentially life-threatening nature of HAE attacks, especially those affecting the airways. Applications span prophylactic treatments aimed at reducing the frequency and severity of attacks, acute treatments to address sudden episodes, and newer gene therapies offering long-term solutions. The end-use scope includes hospital settings and home care, driven by patient preferences and improved home-use formulations. Market growth is influenced by increasing awareness, rising diagnosis rates, and continuous advancements in biologics and recombinant therapies. Opportunities lie in expanding geographic reach, especially in developing regions where awareness and availability remain limited. There's a growing potential in personalized medicine, where tailored therapies can significantly improve patient outcomes. Swift innovation in gene therapy and RNA-based treatments also presents promising avenues. However, challenges persist, including high treatment costs, limited patient population due to the rarity of HAE, and stringent regulatory scenarios that may delay drug approvals. Another hurdle is the need for robust infrastructure to support advanced therapies in underdeveloped regions. For businesses, focusing on R&D in cost-effective production methods and effective delivery systems is crucial, as is collaboration with healthcare providers to enhance diagnosis and treatment accessibility. The market is characterized by significant competition from biotechnology firms, with key players investing heavily in next-gen therapeutic solutions. As such, companies should prioritize strategic partnerships and patient education initiatives for competitive advantage. The potential for innovation in devices for early HAE attack detection and monitoring systems represents a burgeoning field for research and development, aimed at improving patients' quality of life through early intervention and efficient treatment management.

KEY MARKET STATISTICS
Base Year [2023]	USD 36.59 billion
Estimated Year [2024]	USD 38.29 billion
Forecast Year [2030]	USD 55.19 billion
CAGR (%)	6.04%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hereditary Angioedema Therapeutics Market

The Hereditary Angioedema Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Increasing cases of hereditary angioedema across the globe
- Surging initiatives to improve the awareness about the disease
- Inadequate treatment of the hereditary angioedema
Market Restraints
- Concern regarding adverse reactions of HAE therapeutics
Market Opportunities
- Rise in approvals of hereditary angioedema drugs
- Potential focus on developing novel therapeutics for hereditary angioedema
Market Challenges
- Lack of awareness about HAE conditions

Porter's Five Forces: A Strategic Tool for Navigating the Hereditary Angioedema Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hereditary Angioedema Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hereditary Angioedema Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hereditary Angioedema Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hereditary Angioedema Therapeutics Market

A detailed market share analysis in the Hereditary Angioedema Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hereditary Angioedema Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hereditary Angioedema Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hereditary Angioedema Therapeutics Market

A strategic analysis of the Hereditary Angioedema Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hereditary Angioedema Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Adverum Biotechnologies, Inc., Arrowhead Pharmaceuticals, Inc., Astria Therapeutics, Inc., Attune Pharmaceuticals, BioCryst Pharmaceuticals, Inc., BioMarin Pharmaceutical Inc., Centogene N.V., Cipla Inc., CSL Limited, Intellia Therapeutics, Inc., Ionis Pharmaceuticals, Inc., KalVista Pharmaceuticals, Inc., Pharming Group N.V., Pharvaris GmbH, and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Hereditary Angioedema Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Drug Class, market is studied across Bradykinin B2 Receptor Antagonist, C1-Esterase Inhibitor, and Kallikrein Inhibitor.
Based on Treatment Type, market is studied across On-Demand and Prophylaxis.
Based on Route Of Administration, market is studied across Intravenous, Oral, and Subcutaneous.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-742BD517F714

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing cases of hereditary angioedema across the globe
  - 5.1.1.2. Surging initiatives to improve the awareness about the disease
  - 5.1.1.3. Inadequate treatment of the hereditary angioedema
- 5.1.2. Restraints
  - 5.1.2.1. Concern regarding adverse reactions of HAE therapeutics
- 5.1.3. Opportunities
  - 5.1.3.1. Rise in approvals of hereditary angioedema drugs
  - 5.1.3.2. Potential focus on developing novel therapeutics for hereditary angioedema
- 5.1.4. Challenges
  - 5.1.4.1. Lack of awareness about HAE conditions
5.2. Market Segmentation Analysis
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Hereditary Angioedema Therapeutics Market, by Drug Class

6.1. Introduction
6.2. Bradykinin B2 Receptor Antagonist
6.3. C1-Esterase Inhibitor
6.4. Kallikrein Inhibitor

7. Hereditary Angioedema Therapeutics Market, by Treatment Type

7.1. Introduction
7.2. On-Demand
7.3. Prophylaxis

8. Hereditary Angioedema Therapeutics Market, by Route Of Administration

8.1. Introduction
8.2. Intravenous
8.3. Oral
8.4. Subcutaneous

9. Americas Hereditary Angioedema Therapeutics Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Hereditary Angioedema Therapeutics Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Hereditary Angioedema Therapeutics Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.4. Strategy Analysis & Recommendation

Companies Mentioned

1. Adverum Biotechnologies, Inc.
2. Arrowhead Pharmaceuticals, Inc.
3. Astria Therapeutics, Inc.
4. Attune Pharmaceuticals
5. BioCryst Pharmaceuticals, Inc.
6. BioMarin Pharmaceutical Inc.
7. Centogene N.V.
8. Cipla Inc.
9. CSL Limited
10. Intellia Therapeutics, Inc.
11. Ionis Pharmaceuticals, Inc.
12. KalVista Pharmaceuticals, Inc.
13. Pharming Group N.V.
14. Pharvaris GmbH
15. Takeda Pharmaceutical Company Limited